Abiopharma

🔍 Scanlon Jennifer F. (Executive)

Company: UL Solutions Inc. (ULS)

Report Date: 2026-06-01

Detailed Transactions and Holdings:

• Sold 7,505 shares of Class A Common Stock at $99.6039 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: false | shares_owned_after: 181,719.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,995 shares of Class A Common Stock at $100.5917 per share (Direct)
  Date: 2026-06-01 | Code: S | equity_swap_involved: false | shares_owned_after: 176,724.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-06-01 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 89,285.00 | Footnotes: F4
• Acquired 200,120 shares of Performance Share Units (Derivative)
  Date: 2026-06-01 | Code: A | equity_swap_involved: false | shares_owned_after: 200,120.00 | transaction_form_type: 4 | Footnotes: F5, F6, F6

Footnotes:

• F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 9, 2025.
• F2: This transaction was executed in multiple trades at prices ranging from $99.08 to $100.02, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: This transaction was executed in multiple trades at prices ranging from $100.09 to $100.98, inclusive. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F4: The Reporting Person's spouse is the trustee of the trust, and the Reporting Person's children are the beneficiaries of the trust.
• F5: Each performance share unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
• F6: The performance share units vest 30% on June 1, 2029, 30% on June 1, 2030, and 40% on June 1, 2031, subject to (i) the Reporting Person's continuous service as Chief Executive Officer (or in another employee role approved by the Issuer's board of directors or a committee thereof) through the applicable vesting date and (ii) the achievement of a stock price metric or relative total shareholder return metric during measurement periods ending on June 1, 2031. The two metrics will be measured independently, and the metric that results in the greater performance percentage will apply for purposes of determining the number of performance share units earned. The amount of performance share units reported herein assumes the target stock price metric is met.